BIOCON GROUP

FACT SHEET
September-12

H1 FY 2013 vs. H1 FY 2012 Q2 FY 2013 vs. Q2 FY 2012

BIOCON LIMITED (CONSOLIDATED) UNAUDITED BALANCE SHEET September 30, 2012 EQUITY AND LIABILITIES Shareholder's Funds (a) Share capital (b)Reserves and surplus Minority interest Non-current liabilities (a) Long-term borrowings (b)Deferred tax liability (net) (c)Other long-term liabilities (d) Long-term provisions

(Rs. Crores) March 31, 2012

100 2,347 2,447 4

100 2,172 2,272 4

125 39 450 4 618

70 583 653

Current liabilities (a)Short-term borrowings (b)Trade payables (c)Other current liabilities (d)Short-term provisions

129 311 364 68 872 3,941

187 348 269 212 1,016 3,945

TOTAL ASSETS Non-current assets (a) Fixed assets (b) Good will on consolidation (c) Non-current investments (d) Deferred tax asset (net) (e) Long term loans and advances (f) Other non-current assets

1,683 12 78 206 186 2,165

1,648 12 64 8 185 29 1,946

Current assets (a) Current Investments (b) Inventories (c)Trade receivables (d)Cash and cash equivalents (e)Short term loans and advances (f)Other current assets

406 405 503 341 82 39 1,776 3,941

492 378 492 523 79 35 1,999 3,945

TOTAL

BIOCON LIMITED (CONSOLIDATED) UNAUDITED PROFIT & LOSS STATEMENT

H1 Particulars FY 13 H1 FY 12

(Rs. Crores)

Variance

INCOME
Biopharmaceuticals Branded formulations - India Total Biopharmaceuticals Contract research Total Sales Other income Total Revenue 734 178 912 252 1,164 71 1,235 570 172 79 109 930 305 4 88 213 43 170 1 169 8.5 640 122 762 180 942 59 1,001 449 137 51 83 720 281 7 88 186 30 156 156 7.8
15% 45% 20% 40% 24% 20% 23%

EXPENDITURE
Material & Power Costs Staff costs Research & Development Other Expenses Manufacturing, staff & other expenses PBDIT /EBITDA Interest and finance charges Depreciation & Amortisation PBT Taxes NET PROFIT FOR THE PERIOD Minority Interest NET PROFIT FOR THE PERIOD, AFTER MINORITY EPS Rs.
2. Figures of the Comparative period have been regrouped wherever necessary Biopharmaceuticals Income includes: Licensing development fees Licensing Income 14 51 27% 26% 54% 31% 29% 8% -36% -1% 14% 44% 9% 8%

Note: 1.The figures are rounded off to the nearest crores, percentages are based on absolute numbers

BIOCON LIMITED (CONSOLIDATED) UNAUDITED PROFIT & LOSS STATEMENT

Q2 Particulars FY 13 Q2 FY 12

(Rs. Crores) Variance

INCOME
Biopharmaceuticals Branded formulations - India Total Biopharmaceuticals Contract research Total Sales Other income Total Revenue 372 91 463 129 592 50 642 291 88 43 54 476 166 1 45 120 30 90 90 4.5 345 65 410 93 503 35 538 237 72 31 49 389 149 2 42 105 19 86 86 4.3 8% 42% 13% 39% 18% 43% 19% 23% 22% 40% 9% 22% 11% -39% 4% 15% 62% 5% 5%

EXPENDITURE
Material & Power Costs Staff costs Research & Development Other Expenses Manufacturing, staff & other expenses PBDIT /EBITDA Interest and finance charges Depreciation & Amortisation PBT Taxes NET PROFIT FOR THE PERIOD Minority Interest NET PROFIT FOR THE PERIOD, AFTER MINORITY EPS Rs.
2. Figures of the Comparative period have been regrouped wherever necessary Biopharmaceuticals Income includes: Licensing development fees Licensing Income 37 -

Note: 1.The figures are rounded off to the nearest crores, percentages are based on absolute numbers